

<b>SOP-QA-3 V6</b>	
<b>Title: Protocol guidance for high risk trials and CTIMPs</b>	
<b>Effective Date: 19-12-24</b>	<b>Review Date: 19-12-27</b>
<b>Author: Ethics &amp; QA Manager and RG Manager</b>	
<b>QA Approval: Richard Cowie, Ethics &amp; QA Manager</b>	
<b>Approver: Prof Seshadri Vasam, R&amp;D Director</b>	
<b>Approver: Prof David Blackburn, Head of School</b>	




GRAMPIAN CLINICAL RESEARCH OFFICE



### Document History

Version	Description of update	Date Effective
5	Clarification of using HRA template for CTIMPs only at 3.1 Clarification of version control for drafts at 3.2 Reference to IRAS and IRCTN numbers at 3.3 Clarification of CTIMP at 3.4 Reference to publically available database at 3.9	6-1-22
6	Reference to CIPs at 1.2 Remove reference to EudraCT number at 3.3	19-12-24

### 1. Scope

- 1.1 This SOP applies to all research and Sponsor staff participating in, or supporting high risk trials, Clinical Trials of Investigational Medicinal Product (CTIMPs) sponsored or co-sponsored by University of Aberdeen (UoA) and/or NHS Grampian (NHSG).
- 1.2 For Medical Device Clinical Investigations (MDCIs) sponsored or co-sponsored by University of Aberdeen (UoA) and/or NHS Grampian (NHSG) a Clinical Investigation Plan (CIP) rather than a Protocol, shall be required. Advice should be sought from Sponsor (researchgovernance@abdn.ac.uk).
- 1.3  Interventional and non-interventional research projects must have a protocol prepared which is compliant with the principles of Good Clinical Practice (GCP).

### 2. Responsibilities








Chief Investigator (CI)	Designing and writing the protocol compliant with the principles of GCP and relevant regulations, appropriate to the research.
Sponsor	Checking the protocol is compliant with the principles of GCP and relevant regulations, appropriate to the research. Ensure any amendments to the protocol are managed correctly.
Research Monitors	Monitoring researchers against the current protocol.

**Uncontrolled when printed. Please ensure that you are working on the most up to date version of this SOP.**


**Key to symbols**  = Important point to note  = Warning

### 3. Procedure

#### CTIMPs and high risk research protocols

- 3.1  The CI, or delegate, must use the Health Research Authority (HRA) Protocol Template (for CTIMPs), available from the HRA website, unless previously discussed and agreed with the Sponsor.
- 3.2  All protocols shall be version controlled; eg 'Draft 1', 'Draft 2', 'Draft 3' etc before being finalised and then recorded as 'V1', 'V2', 'V3' etc. Versions shall **never** be 0.1, 1.1, 1.2, 1.3 etc.
- 3.3  All pages shall be numbered and include the version number, version date and the study title (or acronym). IRAS and ISRCTN numbers can also be included when available.
- 3.4  The Approval Page shall be signed and dated by the Sponsor representative, CI, the individual responsible for statistical review and any other appropriate trial staff **prior** to distribution. If a trial is a CTIMP, the Clinical Trial Pharmacist must also sign the protocol (please note that the HRA template does not include the Clinical Trial Pharmacist and this should be added when required). If laboratory analysis is included in the protocol, the CI must ensure the appropriate laboratory representative (eg Laboratory Manager) has been involved prior to finalising the protocol.  By signing the protocol the individuals concerned are making a formal agreement to adhere to it at all times.
- 3.5 Where appropriate, the protocol may refer to information listed in other documents eg the Summary of Product Characteristics (SPC), Investigator Brochure (IB), Trial Steering Committee (TSC) or Data Monitoring Committee (DMC) remit and membership.
- 3.6 If separate site specific information relating to the protocol is required (eg local handling procedures, storage etc) this shall be provided as an appendix to the protocol.
- 3.7  All planned amendments to the protocol must be submitted in the first instance to the Research Governance Team.
- 3.8 All fully approved amended protocols are subject to the same processes listed above.
- 3.9  In the interests of transparency, University of Aberdeen and NHS-Grampian require that protocols are registered on a publicly accessible database (<https://www.hra.nhs.uk/planning-and-improving-research/research-planning/research-registration-research-project-identifiers/>). This shall create an early scientific record of methodology, help with publication and potentially reduce duplication of some research effort.

**Uncontrolled when printed. Please ensure that you are working on the most up to date version of this SOP.**

**Key to symbols**  = Important point to note  = Warning



#### 4. Abbreviations and definitions

CI	Chief Investigator
CIP	Clinical Investigation Plan (MDCI only)
CTIMP	Clinical Trial of Investigational Medicinal Product
DMC	Data Monitoring Committee
GCP	Good Clinical Practice
HRA	Health Research Authority
IB	Investigator Brochure
MDCI	Medical Device Clinical Investigation
SPC (or SmPC)	Summary of Product Characteristics
TSC	Trial Steering Committee

#### 5. Related documentation and references

National Research Ethics Service/Health Research Authority website.

**Uncontrolled when printed. Please ensure that you are working on the most up to date version of this SOP.**

**Key to symbols**  = Important point to note  = Warning